Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry out expensive clinical efficacy studies, experts have said.

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth quarter, but that compared unfavorably with ...

Organon and Shanghai Henlius Biotech have announced that the European Medicines Agency (EMA) has validated a marketing authorisation application for HLX11, a biosimilar candidate referencing Roche’s ...

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...

While early steps have been taken in Austria and France, Belgium MEP Yvan Verougstraete stresses the need for a long-term ...